American tegumentary leishmaniasis: Is antimonial treatment outcome related to parasite drug susceptibility?

Journal of Infectious Diseases

Volumn 194, Issue 8, 2006, Pages 1168-1175

  Yardley, Vanessa ^a   Ortuño, Nimer ^a,b   Llanos Cuentas, Alejandro ^c   Chappuis, François ^d   De Doncker, Simonne ^e   Ramirez, Luis ^c,e   Croft, Simon ^a   Arevalo, Jorge ^c   Adaui, Vanessa ^c   Bermudez, Hernan ^b   Decuypere, Saskia ^e   Dujardin, Jean Claude ^e,f  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b Centro Universitario de Medicina Tropical   (Bolivia)

^c INSTITUTO DE MEDICINA TROPICAL ALEXANDER VON HUMBOLDT   (Peru)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e UNIVERSITY OF ANTWERP   (Belgium)

^f INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMONY; MEGLUMINE ANTIMONATE; STIBOGLUCONATE SODIUM;

AMASTIGOTE; AMERICAN TEGUMENTARY LEISHMANIASIS; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; DRUG CHOICE; DRUG EFFICACY; DRUG SENSITIVITY; HUMAN; IN VITRO STUDY; NONHUMAN; PARASITE ISOLATION; PERU; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; SKIN LEISHMANIASIS; SPECIES DIFFERENCE; STANDARDIZATION;

ANIMALS; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; DRUG RESISTANCE; HUMANS; LEISHMANIA; LEISHMANIASIS, CUTANEOUS; PARASITIC SENSITIVITY TESTS; PERU; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33749632746     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/507710     Document Type: Article

References (33)

1. Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg 2001; 95:239-43.
2. Dujardin JC. Risk factors in the spread of leishmaniases: towards integrated monitoring? Trends Parasitol 2006; 22:4-6.
3. Sundar S, More DK, Singl MK, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 2000; 31:1104-7.
4. Bermudez H, Rojas E, Garcia L, et al. Efficacy and safety of a generic sodium stibogluconate for the treatment of tegumentary leishmaniasis in Isiboro Secure Park, Bolivia. Ann Trop Med Hyg 2006; 100:591-600.
5. Oliveira-Neto MP, Schubach A, Mattos M, Goncalves-Costa SC, Pirmez C. A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow-up studies (up to 10 years). Am J Trop Med Hyg 1997; 57:651-5.
6. Palacios R, Osorio LE, Grajalew LF, Ochoa MT. Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania Viannia species. Am J Trop Med Hyg 2001; 64:187-93.
7. Bourreau E, Prévot G, Gardon J, Pradinaud R, Launois P. High intralesional interleukin-10 messenger RNA expression in localized cutaneous leishmaniasis is associated with unresponsiveness to treatment. J Infect Dis 2001; 184:1628-30.
8. Nacher M, Carme B, Sainte Marie D, et al. Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana. Ann Trop Med Parasitol 2001; 95:331-6.
9. Franco MA, Barbosa AC, Rath S, Dorea JG. Antimony oxidation states in antileishmanial drugs. Am J Trop Med Hyg 1995; 52:435-7.
10. Allen S, Neal RA. The in vitro susceptibility of macrophages infected with amastigotes of Leishmania spp. to pentavalent antimonial drugs and other compounds with special relevance to cutaneous isolates. In: Hart DT, ed. Leishmaniasis. New York: Plenum Press, 1989:711-20.
11. Lira R, Sundar S, Makharia A, et al. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J Infect Dis 1999; 180:564-7.
12. Abdo MG, Elamin WM, Khalil EA, Mukhtar MM. Antimony-resistant Leishmania donovani in eastern Sudan: incidence and in vitro correlation. East Mediterr Health J 2003; 9:837-43.
13. Grogl M, Thomason TN, Franke ED. Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease. Am J Trop Med Hyg 1992; 47:117-26.
14. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006; 19:111-26.
15. Rojas R, Valderrama L, Valderrama M, Varona MX, Ouellette M, Saravia NG. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. J Infect Dis 2006; 193:1375-83.
16. Lopez M, Inga R, Cangalaya M, et al. Diagnosis of Leishmania using the polymerase chain reaction: a simplified procedure for field work. Am J Trop Med Hyg 1993; 49:348-56.
17. Evans DA. In vitro cultivation and biological cloning of Leishmania. Methods Mol Biol 1993; 21:29-41.
18. Coderre JA, Beverley SM, Schimke RT, Santi DV. Overproduction of a bifunctional thymidylate synthetase-dihydrofolate reductase and DNA amplification in methotrexate-resistant Leishmania tropica. Proc Natl Acad Sci USA 1983; 80:2132-6.
19. Dey T, Afrin F, Anam K, Ali N. Infectivity and virulence of Leishmania donovani promastigotes: a role for media, source, and strain of parasite. J Eukaryot Microbiol 2002; 49:270-4.
20. Victoir K, De Doncker S, Cabrera L, et al. Direct identification of Leishmania species in biopsies from patients with American tegumentary leishmaniasis. Trans R Soc Trop Med Hyg 2003; 97:80-7.
21. Garcia L, Kindt A, Bermudez H, et al. Culture-independent species typing of neotropical Leishmania for clinical validation of a PCR-based assay targeting heat shock protein 70 genes. J Clin Microbiol 2004; 42:2294-7.
22. Garcia AL, Kindt A, Quispe-Tintaya W, et al. American tegumentary leishmaniasis: antigen-gene polymorphism, taxonomy and clinical pleomorphism. Infect Genet Evol 2005; 5:109-16.
23. Neal RA, Croft SL. An in vitro system for determining the activity of compounds against the intracellular amastigote form of Leishmania donovani. J Antimicrob Chemother 1984; 14:463-75.
24. Spangler E, Moreira A, Anacleto C, Petrillo-Peixoto MdL. Effect of glucantime on field and patient isolates of New World Leishmania: use of growth parameters of promastigotes to assess antimony susceptibility. Parasitol Res 1998; 84:720-6.
25. Ephros M, Bitnun A, Shaked P, Waldman E, Zilberstein D. Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes. Antimicrob Agents Chemother 1999; 43:278-82.
26. Neal RA, Croft SL. An in vitro system for determining the activity of compounds against the intracellular amastigote form of Leishmania donovani. J Antimicrob Chemother 1984; 14:463-75.
27. Roberts WL, Berman JD, Rainey PM. In vitro antileishmanial properties of tri- and pentavalent antimonial preparations. Antimicrob Agents Chemother 1995; 39:1234-9.
28. El Fadili K, Messier N, Leprohon P, et al. Role of the ABC transporter MRPA (PGPA) in antimony resistance in Leishmania infantum axenic and intracellular amastigotes. Antimicrob Agents Chemother 2005; 49:1988-93.
29. Travi BL, Adler GH, Lozano M, Cadena H, Montoya-Lerma J. Impact of habitat degradation on phlebotominae (Diptera: Psychodidae) of tropical dry forests in Northern Colombia. J Med Entomol 2002; 39:451-6.
30. Holzmuller P, Sereno D, Lemesre JL. Lower nitric oxide susceptibility of trivalent antimony-resistant amastigotes of Leishmania infantum. Antimicrob Agents Chemother 2005; 49:4406-9.
31. Mendonca SC, Coutinho SG, Amendoeira RR, Marzochi MC, Pirmez C. Human American cutaneous leishmaniasis (Leishmania b. braziliensis) in Brazil: lymphoproliferative responses and influence of therapy. Clin Exp Immunol 1986; 64:269-76.
32. Arevalo I, Ward B, Miller R, et al. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis 2001; 33:1847-51.
33. Miranda-Verástegui C, Llanos-Cuentas A, Arévalo I, Ward BJ, Matlashewski G. Randomized double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru. Clin Infect Dis 2005; 40:1395-403.